Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential
November 17, 2022– Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worsening – – Virtual Multiple Sclerosis…Immunic to Participate in Investor and Scientific Conferences in November and December
November 10, 2022NEW YORK, November 10, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 3, 2022– $72.8 Million in Cash and Cash Equivalents as of September 30, 2022, Plus $56.4 Million of Net Cash Raised…Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
October 27, 2022– Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK, October 27, 2022 – Immunic,…Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate
October 20, 2022– Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo – – No New…Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
October 10, 2022NEW YORK, October 10, 2022 – Immunic, Inc. (Nasdaq: IMUX) (“Immunic” or the “Company”), a clinical-stage biopharmaceutical company developing a…Immunic to Participate in Scientific and Industry Conferences in October
October 4, 2022NEW YORK, October 4, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
September 20, 2022– Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU‑856 in Single and 14-Day Multiple Dosing –…Immunic, Inc. to Participate in Investor Conferences in September
September 1, 2022NEW YORK, September 1, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
August 16, 2022NEW YORK, August 16, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…